Maximus Review: Testosterone & ED Treatment

Maximus requires full lab work before any prescription is issued - total testosterone, free testosterone, LH, FSH, hematocrit, PSA, complete metabolic panel, and often additional markers like SHBG, estradiol, and thyroid function. This full panel is necessary to understand not just whether testosterone is low but the mechanism driving it (primary vs. secondary hypogonadism), the presence of conditions that influence how TRT should be managed, and whether other hormonal systems are contributing to the patient's symptoms. The lab-first requirement is a clinical standard, but what distinguishes Maximus is the depth of interpretation. Providers are looking not just for clinical hypogonadism (T under 300 ng/dL) but for functional suboptimal levels - men whose total testosterone may be in the "normal" range but whose free testosterone is low due to high SHBG, or men in the 300-500 range who have significant symptoms and whose quality of life would be meaningfully improved by optimization. This broader therapeutic window - treating men who are technically normal but functionally suboptimal - is where the optimization framing diverges from standard clinical practice. Traditional endocrinology typically reserves TRT for men with clearly established hypogonadism. Maximus, like other optimization-focused platforms, operates with a more expansive view of who benefits from testosterone support. This approach has advocates and critics in the medical community. The advocates cite evidence that men with testosterone in the low-normal range who are symptomatic show meaningful quality-of-life improvements with treatment. The critics note that the long-term effects of TRT in men with technically normal testosterone are less well-studied. Patients should understand this debate when making their decision.

Maximus integrates testosterone therapy with a broader performance optimization framework that distinguishes it from basic TRT platforms. Alongside medication management, the program includes coaching around the lifestyle variables that interact with testosterone and general performance: sleep optimization, training protocols, nutrition for hormonal health, and recovery strategies.

Testosterone is primarily secreted during deep sleep, and sleep deprivation considerably impairs testosterone production. Men with sleep apnea - which is common in the demographic presenting with low testosterone symptoms - show markedly reduced testosterone levels compared to controls without sleep disorders.

Resistance training protocols are part of the performance framework because strength training increases testosterone production and also improves body composition in ways that are bidirectionally beneficial with TRT. Visceral fat is an estrogen factory (aromatase enzyme in fat tissue converts testosterone to estrogen), and reducing fat mass improves the testosterone-to-estrogen ratio. Training prescriptions that maximize these effects are clinically relevant to testosterone optimization.

Nutrition guidance focuses on the dietary variables associated with testosterone production: adequate healthy fat intake (testosterone is synthesized from cholesterol), micronutrients (zinc, vitamin D, magnesium deficiencies are associated with low testosterone), protein adequacy for muscle preservation, and avoidance of foods that impair testosterone production or raise estrogen.

Maximus offers standard TRT delivery formats with provider selection based on patient circumstance: Testosterone cypionate injections (subcutaneous weekly or intramuscular bi-weekly): The most common TRT formulation. Maximus typically uses weekly subcutaneous injections, which produce more stable levels than bi-weekly intramuscular injections and are better tolerated for self-administration. Dosing typically starts at 100mg/week and is adjusted based on follow-up lab results. Testosterone enanthate: Similar to cypionate with a slightly longer half-life. Used by some providers as an alternative when cypionate is unavailable or as patient preference. Topical testosterone gel/cream: For patients who prefer not to inject. Applied daily to shoulders, upper arms, or inner thighs. Produces more stable levels than injections but requires daily application and carries transfer risk. Human chorionic gonadotropin (hCG): Often used alongside testosterone cypionate in the Maximus protocol. hCG stimulates the Leydig cells in the testes to produce endogenous testosterone, maintaining testicular volume and function and preserving spermatogenesis. This is particularly important for men who are not certain their family is complete - hCG use during TRT reduce considerablys fertility suppression compared to testosterone alone. Enclomiphene: A selective estrogen receptor modulator that blocks the hypothalamic feedback that suppresses LH/FSH production. By blocking this feedback, enclomiphene stimulates the body to produce more testosterone naturally. This is not TRT in the traditional sense - it boosts endogenous production rather than replacing it externally. Maximus uses enclomiphene for men with secondary hypogonadism who want to maintain natural testosterone production and fertility.

When testosterone is elevated through TRT, the body's aromatase enzyme converts a portion of it to estradiol. Elevated estradiol causes symptoms including water retention, mood changes, gynecomastia, and reduced libido - the same symptoms TRT is meant to resolve. Monitoring and managing estradiol is a clinical standard that separates complete TRT programs from basic prescribing.

Maximus monitors estradiol as part of its follow-up labs and manages estrogen excess when it occurs. The management options are:

Aromatase inhibitors (anastrozole, exemestane): Block the conversion of testosterone to estrogen. Anastrozole is commonly used in TRT management. However, over-suppression of estrogen is also problematic - testosterone and estrogen balance is necessary for bone density, cardiovascular health, and cognitive function in men. Judicious use of aromatase inhibitors to bring estradiol into the optimal range (rather than eliminating it) is a clinical skill that not all TRT platforms manage well.

Lifestyle interventions: Reducing body fat (which reduces aromatase activity), optimizing zinc intake (zinc inhibits aromatase), and reducing alcohol consumption (liver metabolism of estrogen is impaired by alcohol) can reduce estrogen conversion without medication.

SERMs: Tamoxifen or clomiphene can address gynecomastia specifically by blocking estrogen receptors in breast tissue.

The attention to estrogen balance is one of the markers of a sophisticated TRT program. Platforms that prescribe testosterone and monitor only testosterone levels - without tracking estradiol and managing the downstream conversion - miss a clinically important variable.

Maximus operates a subscription model priced at approximately $139-199/month depending on the specific program tier and medications included. The subscription includes the testosterone medication, ongoing provider oversight, required monitoring labs at specified intervals, and access to the performance coaching curriculum.

The initial evaluation - which includes the complete lab panel - typically costs $99-149, which covers both the labs and the initial provider consultation to review results and develop a treatment plan. For men who have not previously had a full hormonal panel, this cost is fully justified given what a complete endocrine lab panel costs at retail.

Follow-up monitoring labs (every 3-6 months) may be included in the subscription or billed separately depending on the program tier. Maximus's website details current pricing, which has evolved as the platform has scaled.

The hCG addition to a TRT protocol adds approximately $30-60/month to the base testosterone cost, depending on dose. Enclomiphene as a standalone or adjunctive treatment is priced similarly. Aromatase inhibitor prescriptions are relatively inexpensive generics.

Annual cost for a standard Maximus TRT program runs $1,700-2,500 including the initial evaluation, ongoing subscription, and monitoring labs. This compares favorably to in-person TRT clinics ($200-400/month plus clinic fees) and is similar to other full-service telehealth TRT programs.

Maximus positions its program partly around cognitive performance - the effect of optimized testosterone on focus, motivation, mental clarity, and mood. This framing reflects real clinical evidence: hypogonadism is associated with depression, brain fog, reduced motivation, and cognitive fatigue. Treatment of hypogonadism improves these outcomes in clinical trials.

The extension to "cognitive optimization" in men with normal-to-low-normal testosterone is where the evidence is less definitive. Correlational data shows relationships between testosterone levels and various cognitive performance measures, but the randomized trial evidence for cognitive benefits of TRT in men who are not clearly hypogonadal is more limited.

Maximus's coaching curriculum addresses the behavioral and lifestyle variables that support cognitive performance alongside hormone optimization: sleep quality (as above), stress management protocols, physical training effects on brain health (BDNF production from exercise), and nutritional factors relevant to cognitive function.

The integrated approach - optimizing hormones alongside the behavioral and lifestyle variables that interact with hormones - represents a more complete model for men seeking performance improvement than either TRT alone or lifestyle coaching without attention to hormonal status. Whether men want to frame this as medicine or optimization, the practical program content addresses both the physiological and behavioral dimensions of male vitality.

The TRT telehealth market includes platforms across a spectrum from basic (prescription testosterone with minimal support) to complete (lab-first protocol, ongoing monitoring, lifestyle coaching, estrogen management). Maximus positions in the complete tier alongside platforms like Peter MD and Fountain TRT.

The differentiation between Maximus and Peter MD: Maximus has stronger lifestyle coaching infrastructure and performance-oriented framing; Peter MD has a slightly more traditional clinical approach with comparable lab rigor. Both are appropriate for men who want complete TRT management. The choice often comes down to whether you want the performance optimization narrative (Maximus) or a more clinical framing (Peter MD).

Against basic TRT platforms that prescribe testosterone with minimal monitoring or lifestyle support, Maximus represents a meaningfully higher standard of care. The performance coaching is not just marketing - managing sleep, training, and estrogen balance alongside testosterone replacement produces better outcomes than testosterone alone.

Against in-person TRT clinics, Maximus offers comparable clinical rigor at lower cost and without the requirement for clinic visits. For men in areas with limited access to TRT specialists, or who prefer the telemedicine convenience, Maximus provides a clinically defensible alternative.

Testosterone replacement therapy requires ongoing safety monitoring that Maximus builds systematically into its protocol. The key safety parameters:

Hematocrit monitoring is the most critical TRT safety parameter. TRT raises red blood cell production, and values exceeding 54% indicate polycythemia - a condition that increases cardiovascular risk including stroke and thrombosis - requiring dose reduction or therapeutic phlebotomy.

PSA monitoring: Prostate-specific antigen is measured before starting and at regular intervals. A significant PSA rise prompts urological evaluation.

Cardiovascular review: Men with pre-existing cardiovascular disease require more careful monitoring. The relationship between TRT and cardiovascular outcomes has been studied extensively; current evidence suggests physiological replacement doses are safe for most men, but individual cardiovascular risk assessment at baseline and ongoing is appropriate.

There are situations where Maximus appropriately escalates to in-person specialist care: men who develop polycythemia requiring intervention, significant PSA elevation requiring prostate evaluation, cardiovascular symptoms during treatment, or complex hormonal findings requiring endocrinology subspecialty evaluation. A responsible telehealth TRT platform knows the limits of remote management and makes referrals when in-person evaluation is indicated.